For research use only. Not for therapeutic Use.
CFT1946（Cat No.:I041295）is a selective, small molecule inhibitor developed to target KRAS mutations, particularly KRAS G12V, which is implicated in various cancers, including non-small cell lung cancer and colorectal cancer. By specifically binding to the mutated KRAS protein, CFT1946 blocks its activity, disrupting downstream signaling pathways that drive tumor growth and survival. Preclinical studies have shown that CFT1946 can effectively inhibit tumor progression and improve treatment outcomes in cancers with KRAS G12V mutations. This targeted therapy offers a promising approach to treating KRAS-driven cancers with the potential for reduced side effects.
| CAS Number | 2882165-79-7 |
| Synonyms | (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane |
| Molecular Formula | C45H49F2N11O9S |
| Purity | ≥95% |
| IUPAC Name | (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane |
| InChI | InChI=1S/C45H49F2N11O9S/c1-4-53(2)68(64,65)52-35-8-6-32(46)40(31(35)24-48)67-28-5-7-34-29(19-28)42(61)58(26-49-34)27-22-45(66-25-27)12-17-56(18-13-45)39(60)23-44(63)10-15-55(16-11-44)37-21-36-30(20-33(37)47)41(51-54(36)3)57-14-9-38(59)50-43(57)62/h5-8,19-21,26-27,52,63H,4,9-18,22-23,25H2,1-3H3,(H,50,59,62)/t27-/m1/s1 |
| InChIKey | OCDRMYDQTIPVOI-HHHXNRCGSA-N |
| SMILES | CCN(C)S(=O)(=O)NC1=C(C(=C(C=C1)F)OC2=CC3=C(C=C2)N=CN(C3=O)[C@@H]4CC5(CCN(CC5)C(=O)CC6(CCN(CC6)C7=C(C=C8C(=C7)N(N=C8N9CCC(=O)NC9=O)C)F)O)OC4)C#N |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
